Neonatal exposure with LPS and/or allergen prevents experimental allergic airways disease: development of tolerance using environmental antigens
Related Experiment Video
Updated: Jul 16, 2026

A Method for Generating Pulmonary Neutrophilia Using Aerosolized Lipopolysaccharide
Published on: December 15, 2014
Yufa Wang1, Christine McCusker
1Meakins-Christie Laboratories, 3626 St Urbain, Montreal, Quebec H2X 2P2, Canada.
Insights
Early life exposure to environmental antigens like LPS and allergens can prevent asthma. Neonatal exposure to LPS promotes tolerance, while ovalbumin exposure leads to a T(H)1 response, both reducing allergic reactions.
Area of Science:
- Immunology
- Environmental Health
- Allergy Research
Background:
- Children in rural areas have lower rates of asthma and allergic rhinitis compared to urban children.
- Neonatal exposure to environmental antigens, such as lipopolysaccharide (LPS) and allergens, may explain this difference.
- Understanding early-life immune priming is crucial for allergy prevention.
Purpose of the Study:
- To investigate the impact of neonatal exposure to LPS and/or allergens on immune responses to subsequent allergen challenge.
- To determine how early-life antigen exposure influences the development of allergic airway inflammation and hyperresponsiveness.
Main Methods:
- Newborn mice were exposed to LPS and/or ovalbumin (OVA).
- At 6 weeks, mice were sensitized and challenged with OVA.
- Airway inflammation, hyperresponsiveness, and cytokine profiles (IL-10, IL-13, IFN-gamma) were assessed.
Main Results:
- Neonatal LPS exposure led to tolerance, with reduced airway hyperresponsiveness and decreased IL-13 and IgE.
- Neonatal ovalbumin exposure also resulted in hyporesponsiveness and no specific IgE, but increased IFN-gamma.
- Combined LPS and ovalbumin exposure induced a mixed T(H)1/T(H)2 response with IL-10 and IFN-gamma.
Conclusions:
- Neonatal mucosal exposure to antigens can inhibit allergic responses to environmental allergens.
- Early LPS exposure promotes immune tolerance, while ovalbumin exposure shifts the response towards a T(H)1 pattern.
- Appropriate early-life exposure to environmental antigens may be key for preventing airway allergies.
Background:
Studies show that children in rural environments develop less asthma and allergic rhinitis than their urban counterparts. This may be a result, in part, of neonatal exposure to environmental antigens such as LPS and/or early exposure to allergens.
Objective:
This study examined the effects of neonatal allergen and/or LPS exposure on subsequent immune responses to allergen.
Methods:
Newborn mice were exposed to LPS and/or ovalbumin. At age 6 weeks, these animals were sensitized and challenged with ovalbumin, and airway inflammation, hyperresponsiveness, and cytokine expression were assessed.
Results:
Animals exposed to LPS in the neonatal period developed T cells expressing CD25 and IL-10 on sensitization and challenge. They demonstrated abrogation of airway hyperresponsiveness and significant decreases in IL-13 from bronchoalveolar lavage fluid and in specific IgE. IL-4-expressing spleen cells were also significantly decreased. Mice exposed in the neonatal period to ovalbumin demonstrated airway hyporesponsiveness after subsequent ovalbumin sensitization and challenge and did not produce specific IgE. In contrast, these animals showed increases in IFN-gamma. Animals exposed to both LPS and ovalbumin developed a response characterized by IL-10 and IFN-gamma-expressing T cells.
Conclusion:
This suggests that mucosal antigen exposure in the neonatal period results in inhibition of allergic responses to environmental allergens. Early LPS exposure directs mucosal responses toward tolerance, whereas ovalbumin exposure follows the T(H)1-type response on subsequent sensitization.
Clinical Implications:
This study suggests that prevention of airways allergy may be best achieved by appropriate exposure of the airway mucosa early in life to environmental antigens.
Related Concept Videos
Allergic Reactions
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Asthma I: Introduction

